Ypsomed announced today that it concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors.

Burgdorf, Switzerland-based Ypsomed designed the autoinjectors to administer drugs for the self-treatment of metabolic conditions. It intends to deliver variants of its YpsoMate 1mL autoinjector for various drugs undergoing clinical trials in large quantities. This expands its manufacturing capacities over the coming years.

Novo Nordisk expects to contribute a significant part of the investment for additional production infrastructure. The companies expect availability of a significant capacity of autoinjectors for Novo Nordisk “in the course of 2025.” To reduce dependences, the company plans to offer third-party manufacturers rights under a royalty scheme.

Earlier this year, the company strengthened its commitment to manufacturing in Switzerland. Ypsomed said it expects to create 200 new jobs in Burgdorf and Solothurn in the current financial year, on top of expansions elsewhere. The company aims to substantially increase its manufacturing capacity in several steps until 2031.

Ypsomed said it sees no material financial impact from the agreement on its current 2023/24 fiscal year. It expects contributions to sales beginning in 2025/26.

“The conclusion of this contract marks an important milestone for Ypsomed,” CEO Simon Michel said. “The long-term cooperation supports our growth strategy significantly and in a sustainable way. We are pleased to enable the treatment of people with chronic conditions in a simple and safe way at home with our devices.”

Ypsomed also develops insulin pumps for those with diabetes. Its YpsoPump represents a leading offering as an automated insulin delivery system compatible with certain software and glucose monitors.

More positives for Ypsomed

The bolstering of manufacturing follows about a year of positive developments across the board at Ypsomed. Here are some of the highlights:

• In April 2022, the company partnered with Abbott and Camdiab on automated insulin delivery.
  • The three companies launched the system in November 2022.
  • The artificial pancreas received UK authorization in April of this year.
• In October, the company unveiled a new autoinjector
• This past January, Ypsomed completed the sale of mail-order retailer for diabetes care DiaExpert. This sale allows the company to focus on the manufacture and sale of its own medical technologies.
• Just this month, Ypsomed and S3 Connected Health partnered on digital offerings.